DDP-4抑制剂在2型糖尿病中临床应用进展  

Progress in clinical application of DDP-4 inhibitors for type 2 diabetes

作　　者：杨莉[1] 岳仁宋[1] 

机构地区：[1]成都中医药大学附属医院内分泌科,成都610072

出　　处：《中国新药杂志》2014年第23期2753-2757,共5页Chinese Journal of New Drugs

摘　　要：目的:二肽基肽酶-4(Dipeptidyl Peptidase-4,DPP-4)可以裂解包括胰高血糖素样肽-1(glucagonlike peptide 1,GLP-1)和抑胃肽(glucose-dependent insulinotropic polypeptide,GIP)在内的多种肽类激素,而前两者与2型糖尿病有着密切联系,是近年来2型糖尿病治疗领域研究的热点。本文就DDP-4抑制剂的作用特点、临床应用以及安全性和耐受性做一综述。方法:通过对国内外近期文献进行分析。结果与结论:DDP-4抑制剂不仅具有良好的降糖效果及保护β细胞功能,并且在糖尿病并发症进展中也起着一定的保护作用。Objective： Dipeptidyl peptidase-4 （DDP-4） degrades several peptide hormones including glu- cagon-like peptide 1 （GLP-1） and glucose-dependent insulinotropic polypeptide （GIP）. GLP-1 and GIP are closely related to type 2 diabetes. It is the hot area of the treatment of type 2 diabetes in recent years. In this article, we summarized the characteristics, clinical application, safety and tolerability of DDP-4 inhibitors. Methods： The medical literature in recent years at home and abroad was collected and analyzed. Results and Conclusion： DDP- 4 inhibitors have satisfactory hypoglycemic effects and protect β cells, and are beneficial for preventing diabetic complications as well.

关 键 词：DDP4抑制剂 2型糖尿病 临床应用 

分 类 号：R977.1[医药卫生—药品]